Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093966 | 0.90 | ALDH1A1 (0.44) | ALDH1A1POLBMAPTLMNAKMT2A | |
| SCHEMBL5088978 | 0.82 | ALDH1A1 (0.43) | ALDH1A1POLBMAPTLMNAKMT2A | |
| SCHEMBL448304 | 0.73 | ALDH1A1 (0.43) | ALDH1A1POLBMAPTL3MBTL1CA2 | |
| SCHEMBL443941 | 0.70 | ALDH1A1 (0.42) | ALDH1A1CA2CA1LMNANR1H4 | |
| SCHEMBL7427703 | 0.69 | FOLH1 (0.52) | ALDH1A1NR1H4KMT2A | |
| SCHEMBL5397725 | 0.68 | ALDH1A1 (0.52) | ALDH1A1POLBMAPTL3MBTL1CA2 | |
| SCHEMBL10395862 | 0.68 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2A | |
| SCHEMBL10395861 | 0.68 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2A | |
| SCHEMBL391430 | 0.68 | FOLH1 (0.60) | ALDH1A1MAPTKMT2A | |
| SCHEMBL7440807 | 0.67 | ALDH1A1 (0.53) | ALDH1A1LMNANR1H4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | claimed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | claimed |
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | ALDH1A1 240/4885POLB 2348/4885MAPT 4131/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | ALDH1A1 240/4885POLB 2348/4885MAPT 4131/4885 |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | ALDH1A1 53/4885POLB 4030/4885MAPT 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.